INTELLIA THERAPEUTICS INC's ticker is NTLA and the CUSIP is 45826J105. A total of 279 filers reported holding INTELLIA THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.98 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,392,260 | -19.6% | 44,031 | +3.7% | 0.01% | -18.2% |
| Q2 2023 | $1,731,763 | +16.1% | 42,466 | +6.1% | 0.01% | +10.0% |
| Q1 2023 | $1,491,135 | +6.3% | 40,009 | -0.5% | 0.01% | 0.0% |
| Q4 2022 | $1,402,648 | -30.0% | 40,202 | +12.3% | 0.01% | -33.3% |
| Q3 2022 | $2,003,000 | +9.6% | 35,800 | +1.4% | 0.02% | +25.0% |
| Q2 2022 | $1,827,000 | -27.4% | 35,295 | +1.9% | 0.01% | -14.3% |
| Q1 2022 | $2,517,000 | -42.6% | 34,633 | -6.6% | 0.01% | -36.4% |
| Q4 2021 | $4,383,000 | -13.3% | 37,071 | -1.7% | 0.02% | -18.5% |
| Q3 2021 | $5,058,000 | -12.7% | 37,701 | +5.3% | 0.03% | +35.0% |
| Q2 2021 | $5,796,000 | +125.9% | 35,796 | +12.0% | 0.02% | +122.2% |
| Q1 2021 | $2,566,000 | +61.9% | 31,973 | +9.8% | 0.01% | +50.0% |
| Q4 2020 | $1,585,000 | +165.9% | 29,128 | -2.8% | 0.01% | +100.0% |
| Q3 2020 | $596,000 | +5.9% | 29,964 | +11.8% | 0.00% | 0.0% |
| Q2 2020 | $563,000 | +101.1% | 26,806 | +17.1% | 0.00% | +50.0% |
| Q1 2020 | $280,000 | -21.1% | 22,886 | -5.5% | 0.00% | +100.0% |
| Q4 2019 | $355,000 | +8.9% | 24,209 | -0.8% | 0.00% | 0.0% |
| Q3 2019 | $326,000 | -14.0% | 24,412 | +5.5% | 0.00% | 0.0% |
| Q2 2019 | $379,000 | +4.7% | 23,149 | +9.3% | 0.00% | 0.0% |
| Q1 2019 | $362,000 | +21.1% | 21,187 | -3.1% | 0.00% | 0.0% |
| Q4 2018 | $299,000 | -52.6% | 21,874 | -0.8% | 0.00% | -50.0% |
| Q3 2018 | $631,000 | +6.6% | 22,042 | +1.8% | 0.00% | 0.0% |
| Q2 2018 | $592,000 | +163.1% | 21,645 | +103.2% | 0.00% | +100.0% |
| Q1 2018 | $225,000 | +4.2% | 10,654 | -5.1% | 0.00% | 0.0% |
| Q4 2017 | $216,000 | -8.5% | 11,227 | +18.1% | 0.00% | 0.0% |
| Q3 2017 | $236,000 | +67.4% | 9,509 | +8.1% | 0.00% | 0.0% |
| Q2 2017 | $141,000 | +131.1% | 8,798 | +104.8% | 0.00% | – |
| Q1 2017 | $61,000 | +15.1% | 4,295 | +7.0% | 0.00% | – |
| Q4 2016 | $53,000 | -99.9% | 4,014 | -0.3% | 0.00% | – |
| Q3 2016 | $68,523,000 | -20.2% | 4,026 | +0.1% | 0.00% | – |
| Q2 2016 | $85,827,000 | – | 4,020 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Discovery Value Fund | 561,561 | $17,756,559 | 9.73% |
| MPM BioImpact LLC | 544,639 | $17,221,485 | 4.60% |
| Casdin Capital, LLC | 1,178,075 | $37,250,732 | 4.12% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 1,145,091 | $36,207,777 | 3.72% |
| Atlas Venture Associates IX, LLC | 10,000 | $316,200 | 2.69% |
| Deep Track Capital, LP | 2,000,000 | $63,240,000 | 2.44% |
| ARK Investment Management | 9,948,629 | $314,575,638 | 2.41% |
| Merlin Capital, Inc | 18,526 | $585,792 | 2.19% |
| Orchard Capital Management, LLC | 159,155 | $5,032,481 | 1.86% |
| TANG CAPITAL MANAGEMENT LLC | 397,600 | $12,572,112 | 1.77% |